TechSeeker Profile

Aviragen Therapeutics (AKA: Biota Pharmaceuticals previously doing business as Nabi Biopharmaceuticals)
Profile last edited on: 1/24/2017

Anti-infective drug development
TS Type
Small Corp
Year Founded
Last Involved Year

Key People / Management

  Vivienne Green -- VP of HR

  John Lambert -- Principal Director of Product Devel. Operations

  Damian Lismore -- Chief Financial Officer and Company Sec.

  Dr. Jane Ryan -- VP of Product Devel. & Strategic Marketing

  Simon Tucker -- VP of Research

Location Information

2500 Northwinds Parkway, STe 100
Alpharetta, GA 30009
   () -

Public Profile

Aviragen Therapeutics is focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three product candidates in active clinical development: These include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics currently being evaluated in the Company’s ongoing Phase 2b SPIRITUS trial; BTA585, an oral fusion protein inhibitor in Phase 2 development for the treatment and prevention of respiratory syncytial virus (RSV) infections; and BTA074, a topical antiviral treatment in Phase 2 development for condyloma caused by human papillomavirus types 6 & 11. Formerly doing business as Biota Pharmaceuticals, Inc., and before that Nabi Biopharmaceuticals, is an anti-infective drug development company, with key expertise in respiratory diseases, particularly influenza. Biota developed the neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. The Company’s researches include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza anti-virals, of which the lead product lnavir, is approved for marketing in Japan. The Company’s products include Zanamivir, Inavi, Phoslyra, BioStar OIA FLU and BioStar OIA FLU A/B. Biota, together with its Japanese based partner, Daiichi Sankyo, have developed an inhaled antiviral compounds for influenza, called long acting inhaled neuraminidase inhibitors (LANI). The company was founded in 1967 and is headquartered in Alpharetta, GA.

Extent of SBIR involvement

User Avatar

Synopsis: Techseeker Business Condition

Publicly Traded
Stock Info
Received SBIR $$

Techseeker firm in the news

There are no news available.